Princeton, NJ, United States of America

Olivier Danos

This inventor holds 5 USPTO granted patents and 18 published patent applications and 1 EPO patent. Top assignees: Regenxbio Inc., The Nemours Foundation. Active years: 2025-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Olivier Danos. Retrieved from https://idiyas.com/inventor/olivier-danos-5rkafxh3

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 5 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2025-2026

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Olivier Danos: Innovator in Gene Therapy

Introduction

Olivier Danos is a prominent inventor based in Princeton, NJ (US). He has made significant contributions to the field of gene therapy, particularly in the treatment of rare genetic disorders. His innovative work has the potential to change the lives of individuals diagnosed with mucopolysaccharidosis type IVA (MPS IVA).

Latest Patents

Danos holds a patent for the "Treatment of mucopolysaccharidosis IVA." This patent involves gene therapy methods that utilize recombinant adeno-associated viruses (rAAVs) to deliver human N-acetylgalactosamine-6-sulfate sulfatase (hGALNS) to the bones of patients diagnosed with MPS IVA. The methods outlined in his patent provide a promising approach to treating this challenging condition.

Career Highlights

Throughout his career, Olivier Danos has worked with esteemed organizations such as the Nemours Foundation and Regenxbio Inc. His experience in these institutions has allowed him to advance his research and contribute to the development of innovative therapies.

Collaborations

Danos has collaborated with notable professionals in the field, including Shunji Tomatsu and Kazuki Sawamoto. These partnerships have fostered a collaborative environment that enhances the research and development of gene therapy solutions.

Conclusion

Olivier Danos is a key figure in the advancement of gene therapy for mucopolysaccharidosis type IVA. His innovative patent and collaborative efforts highlight his commitment to improving treatment options for patients with rare genetic disorders.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…